Vnitr Lek 2013, 59(3):204-207

Incretin therapy and diabetic retinopathy

M. Kvapil
Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

Therapy based on incretins presents a new group of medicinal substances designated for an intervention in patients with type 2 diabetes. It includes a therapy that is efficient, safe and effective. Its advantage is a low risk of hypoglycaemia and a positive effect on body weight. The analyses that have been published so far consistently indicate a positive impact on cardiovascular risk factors. The first studies conducted on animal models prove a favourable influence of incretin therapy on the pathophysiology of diabetic retinopathy.

Keywords: diabetes mellitus type 2; gliptins; GLP-1 receptor agonists; diabetic retinopathy

Received: January 18, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kvapil M. Incretin therapy and diabetic retinopathy. Vnitr Lek. 2013;59(3):204-207.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ahrén B. Gut peptides and Type 2 diabetes mellitus treatment. Curr Diab Rep 2003; 3: 365-372. Go to original source... Go to PubMed...
    2. D'Alessio DA, Vahl TP. Glucagon-like peptid 1: evolution of an incretin into a treatment for diabetes. Am J Physiol Endocrinol Metab 2004; 286: E882-E890. Go to original source... Go to PubMed...
    3. De Meester I et al. Natural substrate of dipeptydyl petpidase IV. Adv Exp Med Biol 2000; 477: 67-87. Go to original source... Go to PubMed...
    4. Nauck MA et al. Efficacy and safety of the dipeptidylpeptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone. a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194-205. Go to original source... Go to PubMed...
    5. Amori RE et al. Efficacy and Safety of Incretin Therapy in Type 2 Diabetes: Systematic Review and Meta-analysis. JAMA 2007; 298: 194-206. Go to original source... Go to PubMed...
    6. Deacon CF. Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review. Diabetes Obes Metab 2011; 13: 7-18. Go to original source... Go to PubMed...
    7. Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010; 86: 44-57. Go to original source... Go to PubMed...
    8. Topp GP et al. Differences in Reported Efficacy between Oral Anti-Hyperglycemic Agents Largely Reflect Differences in Baseline A1C. Diabetes 2008; 1: (suppl. 1): A436-A437.
    9. Migoya EM et al. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1. Clin Pharmacol Ther 2010; 88: 801-808. Go to original source... Go to PubMed...
    10. Goldstein BJ et al. Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patiens With Type 2 Diabetes. Diabetes Care 2007; 30: 1979-1987. Go to original source... Go to PubMed...
    11. Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009; 160: 909-917. Go to original source... Go to PubMed...
    12. Pratley RE. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Medscape J Med 2008; 28: 171.
    13. Vilsbøll T et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. Diabet Med 2008; 25: 152-156. Go to original source... Go to PubMed...
    14. Fineman M, Flanagan S, Taylor K et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011; 50: 65-74. Go to original source... Go to PubMed...
    15. DeYoung MB, MacConell L, Sarin V et al. Encapsulation of exenatide in poly-(D,L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther 201; 13: 1145-1154. Go to original source... Go to PubMed...
    16. Murphy CE. Review of the safety and efficacy of exenatide once weekly for the treatment of type 2 diabetes mellitus. Ann Pharmacother 2012; 46: 812-821. Go to original source... Go to PubMed...
    17. Scott LJ. Exenatide extended-release: a review of its use in type 2 diabetes mellitus. Drugs 2012; 72: 1679-1707. Go to original source... Go to PubMed...
    18. Zhang R, Zhang H, Xu L et al. Neuroprotective effect of intravitreal cell-based glucagon-like peptide-1 production in the optic nerve crush model. Acta Ophthalmol 2011; 89: e320-e326. Go to original source... Go to PubMed...
    19. Zhang Y, Zhang J, Wang Q et al. Intravitreal injection of exendin-4 analogue protects retinal cells in early diabetic rats. Invest Ophthalmol Vis Sci 2011; 52: 278-285. Go to original source... Go to PubMed...
    20. Zhang Y, Wang Q, Zhang J et al. Protection of exendin-4 analogue in early experimental diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2009; 247: 699-706. Go to original source... Go to PubMed...
    21. Gonçalves A, Leal E, Paiva A et al. Protective effects of the dipeptidyl peptidase IV inhibitor sitagliptin in the blood-retinal barrier in a type 2 diabetes animal model. Diabetes Obes Metab 2012; 14: 454-463. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.